A securities class action has been filed against aTyr Pharma, Inc. (ATYR) on behalf of all investors who purchased or otherwise acquired aTyr common stock between January 16, 2025 through September 12, 2025. This case has been filed in the USDC – SDCA.
On September 15, 2025, aTyr issued a press release “announce[ing] topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease.” The press release disclosed, in relevant part, that the trial had failed to meet its primary endpoint.
On this news, aTyr’s stock price fell $5.02 per share, or 83.25%, to close at $1.01 per share on September 15, 2025.